Core Viewpoint - The Pudong New Area aims to become a global hub for innovative biopharmaceuticals, targeting significant growth in the industry by 2027, with specific goals for new drug approvals and market expansion [1][2]. Group 1: Industry Growth and Innovation - The biopharmaceutical industry in China is rapidly developing, with Pudong's innovative drug pipeline ranking second globally, surpassing Europe and Japan combined [2]. - Pudong's biopharmaceutical industry scale is projected to grow from 240.8 billion yuan in 2020 to 410 billion yuan by 2024, with an annual compound growth rate of 14% [2]. - The area has received approvals for 24 new drugs and 29 innovative medical devices since 2020, with a notable increase in the number of "First-in-class" and "First-in-China" products [2][3]. Group 2: Regulatory and Institutional Innovations - Pudong is implementing reforms to reduce institutional transaction costs and expedite the approval process for clinical trials and product launches [5]. - The area has established a unified ethical review process for clinical trials, enhancing efficiency in medical ethics reviews [5]. - In 2023, Pudong has introduced 75 innovative products into its medical institutions, with a 63% year-on-year increase in the usage of innovative medical products [5]. Group 3: Entrepreneurial Ecosystem - Pudong is positioning itself as a preferred location for scientists and entrepreneurs by creating low-cost innovation incubation zones and fostering collaboration with universities and research institutions [7]. - The area has seen a significant increase in overseas transactions, with 30% of national trade volume in biopharmaceuticals occurring in Pudong [7]. - The establishment of high-quality incubators and innovation centers in the Zhangjiang area has led to the creation of over 100 new biopharmaceutical startups annually [8][10]. Group 4: Future Development Plans - The Pudong New Area plans to develop a "1+1+X" model for biopharmaceutical functions, focusing on innovation hubs and industry clusters [7][10]. - The area aims to support the growth of large enterprises and significant products through tailored policies and service packages [10].

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年7月25日消息，中欧医疗创新股票A(006228) 最新净值1.6496元，下跌2.19%。该基金近1个 月收益率19.35%，同类排名7|787；近6个月收益率62.55%，同类排 ...

Core Viewpoint - On July 25, the Hang Seng Index fell by 1.09%, closing at 25,388.35 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 20.184 billion [1][2]. Group 1: Market Activity - The total trading volume for the Stock Connect on July 25 was HKD 148.55 billion, with a net purchase of HKD 20.184 billion [1]. - The Shanghai Stock Connect accounted for HKD 92.243 billion in trading volume, with a net purchase of HKD 11.474 billion, while the Shenzhen Stock Connect had a trading volume of HKD 56.308 billion and a net purchase of HKD 8.710 billion [1]. Group 2: Active Stocks - The most actively traded stock in the Shanghai Stock Connect was the Tracker Fund of Hong Kong (盈富基金), with a trading volume of HKD 49.37 billion and a net purchase of HKD 49.02 billion, despite a closing price drop of 1.07% [1][2]. - Other notable stocks included SMIC (中芯国际) and Alibaba (阿里巴巴-W), with trading volumes of HKD 40.80 billion and HKD 26.25 billion, respectively [1]. - In the Shenzhen Stock Connect, the Tracker Fund of Hong Kong also led with a trading volume of HKD 24.22 billion and a net purchase of HKD 23.78 billion, while the stock closed down by 1.07% [2].

Core Insights - The Hang Seng Index fell by 1.09% on July 25, with southbound trading totaling HKD 148.55 billion, including HKD 84.37 billion in buying and HKD 64.18 billion in selling, resulting in a net buying amount of HKD 20.18 billion [1] Trading Activity - The most active stock in southbound trading was the Tracker Fund of Hong Kong (盈富基金), with a total trading amount of HKD 73.58 billion and a net buying amount of HKD 72.80 billion, despite a closing price drop of 1.07% [1][2] - Other notable stocks included SMIC (中芯国际) with a trading amount of HKD 64.69 billion and a net buying of HKD 7.82 billion, and Alibaba (阿里巴巴-W) with a trading amount of HKD 45.97 billion and a net buying of HKD 8.24 million [2] Net Buying and Selling - A total of 9 stocks experienced net buying, with the Tracker Fund of Hong Kong leading at HKD 72.80 billion, followed by the Hang Seng China Enterprises Index (恒生中国企业) with HKD 14.35 billion and China Life (中国人寿) with HKD 9.55 billion [1] - The stock with the highest net selling was Kuaishou (快手-W), with a net selling amount of HKD 6.67 billion and a closing price drop of 4.86% [1][2]

Core Viewpoint - On July 25, WuXi Biologics made its first appearance on the Hong Kong Stock Connect active trading list in a month, indicating increased investor interest in the stock [2]. Group 1: Trading Activity - On July 25, the total trading volume of active stocks on the Hong Kong Stock Connect reached HKD 420.49 billion, accounting for 28.31% of the day's total trading amount [2]. - The net buying amount for the day was HKD 110.89 billion [2]. - The top three stocks by trading volume were: - Tracker Fund of Hong Kong (HKD 73.58 billion) - SMIC (HKD 64.69 billion) - Alibaba-W (HKD 45.97 billion) [2]. Group 2: Stock Performance - WuXi Biologics had a trading volume of HKD 10.13 billion on the same day, with a net sell amount of HKD 1.98 billion, and its stock price increased by 5.53% [2]. - The stocks with the highest number of appearances on the active trading list over the past month were Alibaba-W and Guotai Junan International, each appearing 21 times, indicating strong interest from Hong Kong Stock Connect funds [2].

Investment Rating - The report maintains a "Buy" rating for the gaming industry, specifically for Sands China, due to its resilient performance and aggressive reinvestment strategies [3][6]. Core Insights - In Q2 2025, Macau's gaming gross revenue increased by 8% year-on-year, recovering to 83% of 2019 levels. VIP gaming revenue rose by 23%, while mass market gaming revenue grew by 4% compared to 2019 [3][6]. - Sands China reported net revenue of $1.8 billion, a 3% year-on-year increase and a 5% quarter-on-quarter increase. The adjusted EBITDA was $559 million, down 1% year-on-year but up 3% quarter-on-quarter, recovering to 73% of 2019 levels [3][6]. - The company has implemented aggressive customer reinvestment projects since late April, which have positively impacted performance in May and June. The Londoner project, with 2,405 newly renovated hotel rooms, aims for an annualized EBITDA of $1 billion, achieving $630 million as of Q2 2025 [3][6]. Summary by Sections Overseas Social Services - Sands China's Q2 2025 performance shows resilience, driven by limited supply, concert events, and high-end customer demand. The company has seen improvements due to aggressive reinvestment strategies [3][6][7]. Overseas Pharmaceuticals - WuXi Biologics expects a revenue increase of approximately 16% year-on-year for 1H25, with a gross margin improvement of about 3.6%. The net profit is projected to grow by around 56% [10][11]. - WuXi AppTec anticipates a revenue increase of over 60% for 1H25, with adjusted net profit growth exceeding 67% [10][11]. Overseas Education - The report suggests focusing on vocational education companies, particularly China Oriental Education, due to a rebound in vocational training demand and operational adjustments expected to enhance profitability [19][20]. - The education index has seen a year-to-date increase of 15.56%, although it underperformed compared to the Hang Seng Index [17].

Market Overview - The Hong Kong stock market experienced a pullback today, with the Hang Seng Index and Hang Seng Tech Index both declining over 1%. However, southbound capital saw accelerated inflows, with a net purchase amount of HKD 20.184 billion in a single day [1] - The innovative drug sector remained active throughout the day, showing resilience despite a midday pullback. The Hong Kong Stock Connect Innovative Drug ETF (520880) reached a historical high, with an intraday increase of 2.89% and a closing increase of 0.61%, with a trading volume of HKD 222 million [1][4] Company Performance - Notable individual stock movements included WuXi Biologics, which surged over 8% at one point and closed up more than 5%. Other gainers included Crystal Digital Holdings, Green Leaf Pharmaceutical, and Xiansheng Pharmaceutical, all showing significant increases [3] - WuXi Biologics announced an expected revenue growth of over 60% year-on-year for the first half of the year, with net profit expected to grow over 50%, exceeding market expectations [3] Industry Trends - The innovative drug sector in Hong Kong has shown strong performance this year, with the Hang Seng Stock Connect Innovative Drug Select Index rising 58.95% year-to-date, outperforming other indices by significant margins [6][9] - According to the National Medical Products Administration, 43 innovative drugs were approved in China in the first half of the year, a year-on-year increase of 59%, nearing the total expected for 2024 [5] - Goldman Sachs noted that Chinese biotech companies contribute nearly 33% to global innovation, while their overall market capitalization is only 14%-15% of their U.S. counterparts [6] Future Outlook - HSBC Qianhai Securities anticipates that the innovative drug sector's valuation has not yet fully reflected its growth potential, with at least three catalysts expected to support the sector in the second half of the year [6] - Upcoming academic conferences, active overseas licensing deals, and a favorable policy environment are expected to drive further momentum in the innovative drug sector [6][7]

Market Overview - The A-share market faced resistance at 3600 points due to the rapid decline of the Yasha Hydropower Station, while the Hong Kong market dropped 1.09% amid uncertainties for the upcoming week [1] - Trump's visit to the Federal Reserve is seen as an attempt to pressure Powell for a quicker interest rate cut, although a rate cut in July seems unrealistic [1] - The upcoming US-China talks scheduled from July 27 to 30 in Sweden may influence market sentiment, particularly regarding TikTok's operations in the US [1] Technology Sector - The 2025 World Artificial Intelligence Conference in Shanghai is set to showcase over 800 companies and 3000 cutting-edge exhibits, indicating strong market interest in AI technologies [2] - Huawei's Ascend 384 super node is a focal point of attention, with significant advancements in the domestic lithography machine industry expected to accelerate the localization process [3] Southeast Asia Market Expansion - Companies like Jihong Holdings and Lion Group are focusing on Southeast Asia, with Jihong expected to achieve a net profit of approximately 130 to 137 million yuan in the first half of 2025, marking a year-on-year growth of 97.25% to 108.21% [4] - Lion Group's partnership with China Post Hong Kong aims to create an AI-driven digital trade platform for Chinese brands entering Southeast Asia [4] Shipping Industry - Derxiang Shipping reported a 38.5% increase in revenue to approximately $326 million in Q1, driven by a 39.1% rise in average freight rates [9] - The company is expanding its service network with new routes and has a strong focus on the Middle East and Indian subcontinent, which are expected to drive future growth [11] Insurance Sector - The insurance industry is experiencing a "lock-in wave" due to a decrease in the predetermined interest rate for life insurance products, which is expected to boost new policy premiums in Q3 [7] - Major beneficiaries in the Hong Kong market include Zhong An Online, China Life, and China Pacific Insurance [8]

Market Overview - A-shares experienced fluctuations with the three major indices slightly declining, and the Shanghai Composite Index falling below 3600 points, with a total trading volume of 1.79 trillion yuan [1] - Market hotspots were mixed, with the number of rising and falling stocks being roughly equal, but the Sci-Tech Innovation Board saw a late surge, shifting funds from cyclical stocks to technology stocks [1] Key Industry Performances - The Sci-Tech Innovation Board's artificial intelligence sector showed significant elasticity, with stocks like Cambricon Technologies rising over 12%, and the Huabao AI ETF (589520) surging 4.81%, leading the market in industry-themed ETFs [1][3] - Other hard technology ETFs, including those focused on big data, electronic technology, and innovative enterprises, also saw positive performance [1] Medical Sector Insights - The largest medical ETF (512170) in A-shares experienced a strong performance, reaching a new high since November 14, 2024, with a daily increase of 2.47% and an eight-day winning streak [1][9] - The medical sector is benefiting from a shift in policy, with the National Medical Insurance Administration emphasizing a "value over price" approach in medical procurement, which is expected to enhance the industry's valuation recovery [9][14] AI Industry Developments - The upcoming World Artificial Intelligence Conference (WAIC) from July 26-28 is anticipated to drive interest in the AI sector, with significant government attention on domestic AI development [6][7] - The U.S. has also made moves to enhance its AI capabilities, with President Trump announcing an "AI Action Plan" and companies like NVIDIA and AMD resuming sales of AI chips to China, which may alleviate supply chain pressures [6][7] ETF Performance Highlights - The Huabao AI ETF (589520) recorded a trading volume of 38.36 million yuan, with a significant increase of 379% compared to previous trading sessions, indicating strong buying interest [3] - The medical ETF (512170) outperformed the Shanghai Composite Index, with a cumulative increase of 5.46% over the week, highlighting the sector's recovery potential [11] Future Market Outlook - Analysts from Dongfang Securities predict a stable macroeconomic outlook with sufficient liquidity, suggesting that the market's structural activity is likely to continue, with the Shanghai Composite Index potentially challenging last year's high of 3674 points [2] - The focus on structural themes remains crucial, with expectations for a gradual accumulation of necessary conditions for a bull market by the fourth quarter of 2025 [2]

Investment Rating - The industry is rated as "Positive" for the next 12 months, indicating an expected increase in performance relative to the CSI 300 index [8][58]. Core Insights - The report highlights the optimization of centralized procurement rules, which aims to stabilize clinical practices, ensure quality, and prevent excessive competition in the pharmaceutical sector. This is expected to benefit pharmaceutical and medical device sectors [6][57]. - The report emphasizes the importance of monitoring the progress of the commercial insurance innovative drug catalog and the performance of companies exceeding expectations in their semi-annual reports. It suggests focusing on pipeline realization, performance growth, and business collaborations within the innovative drug and related industry chain [6][57]. - The report notes significant developments in the pharmaceutical industry, including the approval of new drug indications and strategic partnerships for drug development, which are expected to enhance market opportunities [19][29][34]. Industry News - In the first half of 2025, the employee medical insurance personal account mutual aid involved 200 million people, with a total mutual aid amount of 26.177 billion yuan [5][18]. - The Shanghai Pudong New Area government has issued a plan to enhance the functions of the biopharmaceutical industry park from 2025 to 2027, aiming for an industry scale exceeding 500 billion yuan by 2027 [18]. - The report mentions the approval of Novo Nordisk's semaglutide for treating chronic kidney disease in China, which is a significant advancement in the industry [19]. Market Performance - During the week of July 18-24, 2025, the Shanghai Composite Index rose by 2.53%, the Shenzhen Component Index increased by 2.94%, and the pharmaceutical and biological sector also saw a rise of 2.94%. All sub-sectors experienced growth, with medical services leading at 6.16% [6][44]. - As of July 24, 2025, the price-to-earnings ratio (TTM) for the pharmaceutical and biological industry was 30.59 times, with a valuation premium of 155% relative to the CSI 300 index [6][48]. Company Announcements - Lizhu Group's clinical trial for a humanized monoclonal antibody injection reached its primary endpoint, indicating progress in its development pipeline [29]. - WuXi Biologics and WuXi AppTec both issued positive profit forecasts, with expected revenue growth of approximately 16% and over 60%, respectively, for the first half of 2025 [32][33].